Flu Season Alert!Alerta de temporada de influenza:
Don’t let germs win this season – protect yourself and your family!
The flu vaccine is your best defense against flu and related complications – PLUS, it is a covered benefit for Texas Children’s Health Plan members! Learn more!
¡No permitas que los gérmenes ganen esta temporada! ¡Protégete a ti y a tu familia!
La vacuna contra la influenza es tu mejor defensa contra la influenza y sus complicaciones. Además, ¡es un beneficio cubierto para los miembros de Texas Children's Health Plan! Aprende más
Change in Preferred Drug List Status for Glucocorticoids, Inhaled Drug Class
Date: May 12, 2025
Attention: Prescribers
Effective date: May 6, 2025
Call to action: Due to the shortage, Health and Human services Commission (HHSC) removed the non-preferred status of the drugs in the table below from the authorized generic (AG) fluticasone HFA products on the preferred drug list (PDL), effective May 6, 2025.
Background: The manufacturers of brand-name Asmanex HFA, Organon, and QVAR RediHaler, Teva
Pharmaceuticals, reported product backorders due to distribution and manufacturing delays.
How this impacts providers: These changes allow providers to prescribe the AG fluticasone HFA products without requiring a PDL prior authorization and continue access to necessary asthma control medications for members.
NDC
Drug Name
66993-0078-96
FLUTICASONE PROP HFA 44 MCG
66993-0079-96
FLUTICASONE PROP HFA 110 MCG
66993-0080-96
FLUTICASONE PROP HFA 220 MCG
Next step for Providers: Prescribers are encouraged to proactively obtain a prescription for the preferred alternatives to avoid disruption in patient’s therapy. Prescribers should share this communication with their staff.
If you have any questions, please email Provider Relations at tchppharmacy@texaschildrens.org.
